{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:54:42Z","timestamp":1777420482487,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Concurrent use of oxycodone and strong cytochrome P450 2D6 (CYP2D6)-inhibiting selective serotonin reuptake inhibitors (SSRIs), specifically paroxetine and fluoxetine, is associated with the risk of opioid overdose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study assessed the association between the duration of concurrent oxycodone and CYP2D6-inhibiting SSRI use and overdose risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective cohort study conducted using the Merative MarketScan claims database from January 1, 2017, to December 31, 2019. Adults aged \u226518 years with private insurance who initiated both oxycodone and SSRIs were included. Patients were grouped as (1) oxycodone with other SSRIs (reference); (2) oxycodone with paroxetine or fluoxetine with &lt;14 days of overlap; and (3) oxycodone with paroxetine or fluoxetine with \u226514 days of overlap. The primary outcome was opioid overdose. Cox proportional hazards models estimated adjusted hazard ratios (HRs), adjusting for demographics, comorbidities, and prior medication use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 97\u2009446 patients met inclusion criteria (mean age 46.4 years; 73.6% female). Among these, 26\u2009967 (27.7%) used oxycodone with CYP2D6-inhibiting SSRIs; 86% of them had &lt;14 days of overlapping therapy. The risk of overdose increased with longer durations of overlapping oxycodone and CYP2D6-inhibiting SSRI use. Compared with patients using other SSRIs, the adjusted HR for opioid overdose was 0.98 (95% CI, 0.65\u20131.01) for &lt;14 days of concurrent use, and 1.24 (95% CI, 1.03\u20131.50) for \u226514 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>Prolonged concurrent use (\u226514 days) of oxycodone with paroxetine or fluoxetine was associated with an increased risk of opioid overdose compared with use with other SSRIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251372646","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T05:39:57Z","timestamp":1759988397000},"page":"425-434","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Duration of Concurrent Oxycodone and Selective Serotonin Reuptake Inhibitors Use and the Risk of Opioid Overdose"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-0942","authenticated-orcid":false,"given":"Chijioke","family":"Okeke","sequence":"first","affiliation":[{"name":"The Prescription Drug Misuse Education and Research (PREMIER) Center, College of Pharmacy, University of Houston, Houston, TX, USA"},{"name":"Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olajumoke","family":"Olateju","sequence":"additional","affiliation":[{"name":"The Prescription Drug Misuse Education and Research (PREMIER) Center, College of Pharmacy, University of Houston, Houston, TX, USA"},{"name":"Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-8561","authenticated-orcid":false,"given":"Ismaeel","family":"Yunusa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prachet","family":"Bhatt","sequence":"additional","affiliation":[{"name":"The Prescription Drug Misuse Education and Research (PREMIER) Center, College of Pharmacy, University of Houston, Houston, TX, USA"},{"name":"Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Douglas","family":"Thornton","sequence":"additional","affiliation":[{"name":"The Prescription Drug Misuse Education and Research (PREMIER) Center, College of Pharmacy, University of Houston, Houston, TX, USA"},{"name":"Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2018.1517175"},{"key":"e_1_3_3_3_2","unstructured":"National Institute of Drug Abuse. Drug overdose deaths: facts and figures. Accessed October 24 2024. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03267-w"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.psy.0000204851.15499.fc"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy8030154"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint13030038"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389200023338017"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5014"},{"key":"e_1_3_3_10_2","unstructured":"Indiana University. Drug interactions Flockhart table. Accessed August 31 2025. https:\/\/drug-interactions.medicine.iu.edu\/MainTable.aspx"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjpain.2009.09.003"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.08.013"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0194"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_3_15_2","unstructured":"MarketScan Research Databases. Accessed November 12 2024. https:\/\/www.merative.com\/documents\/brief\/marketscan-explainer-general"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.112"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1266-x"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200702000-00005"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050163"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-00731-3"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199708020-00010"},{"key":"e_1_3_3_22_2","unstructured":"Fluoxetine Capsules USP. Accessed April 20 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/018936s088 020101s042 021235s014lbl.pdf"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0919"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2019-000483"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj149"},{"key":"e_1_3_3_26_2","unstructured":"Agency for Healthcare Research Quality (AHRQ). Clinical classifications software refined (CCSR) for ICD-10-CM diagnoses. Accessed October 10 2024. https:\/\/hcup-us.ahrq.gov\/toolssoftware\/ccsr\/dxccsr.jsp"},{"key":"e_1_3_3_27_2","unstructured":"National Library of Medicine. RxNav. Accessed October 10 2024. https:\/\/lhncbc.nlm.nih.gov\/RxNav\/index.html"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12174"},{"key":"e_1_3_3_29_2","unstructured":"Kane M. Oxycodone therapy and CYP2D6 genotype. In: Pratt VM Scott SA Pirmohamed M eds. Medical Genetics Summaries. National Center for Biotechnology Information; 2012. Accessed October 10 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK584639\/"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00673.x"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0036-0"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03653.x"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2361"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200904"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000019"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1243"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6373"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000021"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.370"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251372646","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251372646","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251372646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:19Z","timestamp":1777374859000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251372646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/10600280251372646"],"URL":"https:\/\/doi.org\/10.1177\/10600280251372646","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}